Short Interest in NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Decreases By 18.6%

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) was the recipient of a large decrease in short interest in March. As of March 13th, there was short interest totaling 87,465 shares, a decrease of 18.6% from the February 26th total of 107,470 shares. Based on an average daily volume of 277,036 shares, the short-interest ratio is presently 0.3 days. Currently, 0.2% of the shares of the company are short sold.

NeuroOne Medical Technologies Stock Performance

NeuroOne Medical Technologies stock remained flat at $0.73 during mid-day trading on Monday. 63,021 shares of the company’s stock were exchanged, compared to its average volume of 257,856. The company has a fifty day moving average of $0.78 and a two-hundred day moving average of $0.79. The firm has a market cap of $37.09 million, a P/E ratio of -4.32 and a beta of 0.74. NeuroOne Medical Technologies has a 1 year low of $0.40 and a 1 year high of $1.16.

NeuroOne Medical Technologies (NASDAQ:NMTC) last announced its quarterly earnings results on Tuesday, February 17th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.01. NeuroOne Medical Technologies had a negative net margin of 78.34% and a negative return on equity of 119.92%. The company had revenue of $2.89 million during the quarter, compared to the consensus estimate of $2.47 million.

Analysts Set New Price Targets

A number of research firms have commented on NMTC. JonesTrading assumed coverage on NeuroOne Medical Technologies in a research note on Monday, March 2nd. They set a “buy” rating and a $1.50 price objective on the stock. Zacks Research lowered NeuroOne Medical Technologies from a “strong-buy” rating to a “hold” rating in a report on Friday, March 13th. Finally, Wall Street Zen upgraded NeuroOne Medical Technologies to a “sell” rating in a research report on Saturday, February 21st. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $1.98.

Insider Activity at NeuroOne Medical Technologies

In other NeuroOne Medical Technologies news, insider David J. Wambeke bought 1,000,000 shares of the stock in a transaction dated Sunday, March 1st. The shares were bought at an average cost of $0.67 per share, with a total value of $670,000.00. Following the completion of the acquisition, the insider owned 1,000,000 shares of the company’s stock, valued at $670,000. This trade represents a ? increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Insiders have sold 14,637 shares of company stock worth $11,710 over the last quarter. 11.80% of the stock is currently owned by company insiders.

Institutional Trading of NeuroOne Medical Technologies

A number of hedge funds have recently made changes to their positions in the company. Focus Financial Network Inc. bought a new stake in shares of NeuroOne Medical Technologies during the third quarter worth about $31,000. Legato Capital Management LLC acquired a new stake in NeuroOne Medical Technologies during the 4th quarter worth approximately $34,000. Squarepoint Ops LLC acquired a new stake in NeuroOne Medical Technologies during the 4th quarter worth approximately $36,000. Susquehanna International Group LLP bought a new stake in NeuroOne Medical Technologies during the 3rd quarter worth approximately $47,000. Finally, XTX Topco Ltd acquired a new position in NeuroOne Medical Technologies in the 2nd quarter valued at approximately $51,000. 16.07% of the stock is owned by institutional investors and hedge funds.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.